Literature DB >> 14493052

Use of 5-fluorouracil in disseminated solid neoplasms.

D B ROCHLIN, J SHINER, E LANGDON, R OTTOMAN.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy; URACIL/related compounds

Mesh：

Substances：

Year:  1962        PMID： 14493052      PMCID： PMC1466269          DOI： 10.1097/00000658-196207000-00020

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  3 in total

1.  Further clinical studies with 5-fluorouracil.

Authors:  F J ANSFIELD; A R CURRERI
Journal:  J Natl Cancer Inst       Date:  1959-03       Impact factor: 13.506

2.  Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.

Authors:  C HEIDELBERGER; N K CHAUDHURI; P DANNEBERG; D MOOREN; L GRIESBACH; R DUSCHINSKY; R J SCHNITZER; E PLEVEN; J SCHEINER
Journal:  Nature       Date:  1957-03-30       Impact factor: 49.962

3.  Clinical studies with 5-fluorouracil.

Authors:  A R CURRERI; F J ANSFIELD; F A McIVER; H A WAISMAN; C HEIDELBERGER
Journal:  Cancer Res       Date:  1958-05       Impact factor: 12.701
  3 in total
  3 in total

1.  5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.

Authors:  M J BRENNAN; R W TALLEY; E H DRAKE; V K VAITKEVICIUS; A K POZNANSKI; B E BRUSH
Journal:  Ann Surg       Date:  1963-09       Impact factor: 12.969

2.  Chemotherapy for the carcinoid syndrome.

Authors:  A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.

Authors:  R E Falk; M Hardy; L Makowka; J Teodorczyk-Injeyan; J A Falk
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.